EXCLUSIVE DISTRIBUTORSHIP AGREEMENT
EXCLUSIVE DISTRIBUTORSHIP AGREEMENT dated as of this 27th of December,
1996, by and between NISSHO CORPORATION, a corporation organized under the laws
of Japan and having its principal place of business at 0-0-0, Xxxxx-Xxxxx,
Xxxx-xx, Xxxxx 00X Xxxxx ("Nissho") and DELCATH SYSTEMS, INC., a corporation
organized under the laws of the State of Delaware and having its principal place
of business at 0000 Xxxxxx Xxxxxx, 0xx Xxxxx, Xxxxxxxx, Xxxxxxxxxxx 00000
("Delcath").
W I T N E S S E T H:
- - - - - - - - - -
IN CONSIDERATION of the mutual promises and covenants herein contained,
the parties hereto hereby agree as follows:
I. DEFINITIONS
Capitalized terms used in the Agreement shall be
defined as follows:
1.1 "Agreement" shall mean this EXCLUSIVE DISTRIBUTORSHIP AGREEMENT.
1.2 "Confidential Information" shall mean all written information and data
provided by the parties to each other hereunder and marked as confidential,
except any portion thereof which:
(a) is known to the receiving party, as evidenced by the
receiving party's written record, before receipt hereof under this
Agreement;
(b) is disclosed to the receiving party by a third
person who has a right to make such disclosure; or
(c) is or becomes part of the public domain through no
fault of the receiving party.
1.3 "Patents" shall mean the patents and patent applications described in
Schedule A attached hereto and made a part hereof.
1.4 "Products" shall mean those products manufactured by Delcath which are
listed on Schedule B attached hereto and made a part hereof. New Products may be
added to Schedule B from time to time by mutual agreement of the Parties.
1.5 "Product Specifications" shall mean the specifications for the Products
set forth in Schedule B attached hereto and made a part hereof. Specifications
may be amended from time to time by mutual agreement of the parties.
Specifications for new Products shall be added to Schedule B from tune to time
by mutual agreement of the parties.
1.6 "Territory" shall mean Japan, Korea, China, Taiwan and Hong Kong.
II. APPOINTMENT AND ACCEPTANCE
2.1 Appointment. Delcath hereby appoints Nissho as its exclusive
distributor within the Territory for the promotion, sale and delivery of the
Products.
2.2 Acceptance. Nissho hereby accepts the foregoing appointment and agrees
to use its reasonable best efforts to secure regulatory approval in the
Territory for, to develop and promote the use and sale of, to sell and deliver,
service, and assure customer satisfaction for, the Products within the
Territory.
2.3 Assistance. Delcath agrees to assist and cooperate with Nissho in
marketing and securing regulatory approval for the Products during the term of
this Agreement. Such assistance includes sale to Nissho of such quantity of
Products reasonably required by Nissho for purposes of clinical trials and
marketing demonstration in any country in the Territory. The price of products
sold for such purposes shall be 10% above Delcath's cost, with all freight,
shipping and insurance costs to be paid by Nissho as set forth in Section 3.5.
III. TERMS AND CONDITIONS OF SALE
3.1 Orders. Nissho shall purchase the Products from Delcath in accordance
with the order and forecast procedure set forth in Schedule C attached hereto
and made a part hereof.
3.2 Prices. Prices for the Products as of the date hereof shall be
determined as set forth on Schedule D attached hereto and made a part hereof.
3.3 Payment Terms. Unless otherwise agreed at the time an order for
Products is placed, Nissho shall provide to Delcath an irrevocable letter of
credit in favor of Delcath and payable at sight. The letter of credit must
either be issued or confirmed by a bank acceptable to Delcath. The letter of
credit shall be in U.S. Dollars in an amount equal to the purchase price of the
Products ordered. All banking charges to open and maintain such letter of credit
are for Nissho's account.
3.4 Taxes. Nissho shall bear all taxes and duties which shall be levied
upon the products within the Territory.
3.5 Delivery. Products shall be shipped F.O.B. from the place of
manufacture by Delcath, with all freight and insurance premium costs to be paid
by Nissho, by such carrier or carriers as Nissho may select. Title and risk of
loss shall pass to Nissho upon acceptance of products by the carrier for
delivery to Nissho. Delcath shall be required to ship Products to no more than
two destinations, designated by Nissho, in the Territory. Nissho may change such
destinations, no more frequently than one time in each calendar year, by giving
90 days written notice to Delcath of such change.
2
3.6 Inspection. Within thirty (30) days after receipt of Products at the
facility specified by Nissho, Nissho may reject any of such Products which fail
to meet the Product Specifications by sending Delcath notice of the lot numbers
or other identifying data of rejected products, together with an indication of
the specific basis for rejection, and Nissho shall within sixty (60) days of
delivery return to Delcath, at Delcath's expense, any such rejected Products,
unless such Products prove to have been improperly rejected, in which event the
expense of returning such Products shall be borne by Nissho. Delcath shall
credit Nissho's account and/or refund to Nissho the purchase price of any such
rejected Products which have been properly rejected.
IV. REGULATORY MATTERS
4.1 Registration of Products in the Territory. Nissho shall obtain, at
Nissho's expense, all registrations and regulatory approvals necessary to
promote, sell and use the Products in any country in the Territory. To this end,
Nissho shall use its best efforts:
(i) To obtain approval by the Ministry of Health of Japan
("MOH") of Nissho's application to conduct human
clinical trials of the first Product within six (6)
months of the date of this Agreement;
(ii) To complete human clinical trials of the first
Product within twelve (12) months of the approval
to conduct clinical trials;
(iii) To file its application for approval by the MOH of
the first Product as a medical device for commercial
sale within six (6) months of the completion of
clinical trials;
(iv) To obtain approval of the MOH of the first Product as
a medical device for commercial sale within twelve
(12) months of the date of its application being
filed; and
(v) To obtain a reimbursement price in Japan for the
first Product within twelve (12) months of the date
of approval for commercial sale by the MOH.
4.2 Traceability. Delcath and Nissho shall each maintain such traceability
records with respect to the Products as shall be necessary to comply with
applicable Good Manufacturing Practices Regulations.
4.3 Complaint Files. Each party shall maintain complaint files relating to
the Products.
4.4 Reliability Reporting. Each party shall promptly report in writing to
the other any failure of a Product, change in the statistically demonstrated
reliability of a Product or other material information relevant to the
reliability of a Product.
3
4.5 Recall or Advisory Actions. Each of Delcath and Nissho shall have the
right to decide whether to recall a Product in the Territory or issue an
advisory letter regarding reliability of or defects in a Product, upon obtaining
the written consent of the other party to this Agreement, which consent shall
not be unreasonably withheld or delayed. Each party shall notify the other in a
timely manner prior to making such recall or issuing such advisory letter. Each
party shall endeavor to reach an agreement with the other regarding the manner,
text and timing of any publicity to be given such matters in time to comply with
any applicable regulatory requirements, but such agreement shall not be a
precondition to any action that either Delcath or Nissho reasonably deems
necessary to protect users of the Product or to comply with any applicable
governmental orders. The party responsible for that aspect of the Product upon
which the recall is based, shall reimburse the other party for reasonable
expenses incurred in handling the recall.
V. TERM AND TERMINATION
5.1 Effective Date and Term. This Agreement shall become effective as of
the date first above written (the "Effective Date"), and shall remain in full
force and effect until the date falling five years following the earliest date
of approval of and establishment of a reimbursement price for any of the
Products for sale and distribution in Japan, but in no event later than December
31, 2004. If, however, Nissho is successful in meeting the "best efforts"
timetable in Article 4.1, the initial term shall end December 31, 2005. The term
of this agreement may be extended for one or more terms of five years following
the date on which this Agreement is otherwise scheduled to terminate provided:
(i) during the period beginning nine months, and ending
six months, prior to the scheduled date of
termination of this Agreement, Nissho gives Delcath
notice of its intention to so extend the term of this
Agreement, and
(ii) Delcath, during the three-month period following its
receipt of the notice described in clause (i) above,
gives notice to Nissho of its intention to so extend
the term of this Agreement. Delcath will, in any
event, reply to the notice provided by Nissho in
clause (i) above within the three-month period
following its receipt.
In the event of any such extension, the terms and conditions of this Agreement
shall otherwise remain in full force and effect unless the parties agree in
writing to any appropriate change or modification.
5.2 Termination. Notwithstanding Sections 2.1 and 5.1 hereof, the parties
agree to the following provisions:
(a) (i) in the event that Nissho or Delcath
shall fail in any material respect to
observe or perform any of the provisions of
this Agreement on its part to be observed or
performed, and if any such failure shall not
be remedied within sixty (60) calendar days
or, in the case of payments due, within
4
thirty (30) calendar days after receipt of
written notice from the other party
specifying such failure, or
(ii) if Nissho or Delcath shall become insolvent
or a receiver shall be appointed for its
business or properties, or if any petition
shall be filed by or against it under any
provisions of any bankruptcy, insolvency or
similar laws,
the other party may, at its option, terminate this Agreement upon giving written
notice of termination to such first party.
(b) If any material agreement or obligation of a party under
this Agreement is held by judgment, rule, order or decree to be invalid by any
court, commission or governmental authority in the Territory, the other party
may, at its option, terminate this Agreement, effective immediately, upon giving
the other party written notice of such termination.
(c) If, at the end of any full calendar year following the
first anniversary of the date of regulatory approval of, and in countries where
applicable, establishment of a reimbursement price for, a Product in any country
in the Territory, Nissho shall fail to purchase and sell in such country during
such year and any preceding year the Minimum Annual Purchase Quantity (as
hereinafter defined) of any Product for that country, Delcath may, at its
option, (i) terminate this Agreement in such country with respect to such
Product or all Products, or (ii) make Nissho's rights hereunder non-exclusive in
such country for such Product or all Products.
VI. CERTAIN COVENANTS
6.1 Notices of Injuries. In any case in which either party receives a
written claim for damages for, or other notice of bodily injury alleged to have
been caused by the Products, such party shall promptly and in any case within
sixty (60) days thereafter give notice of any possible claim to the other party
and shall cooperate fully with the other party in the defense of all such
claims.
6.2 Confidential Information. It is contemplated that in the course of the
performance of this Agreement each party may, from time to time, disclose
Confidential Information to the other. Each party agrees to take all reasonable
steps to prevent disclosure of Confidential Information; provided, however, no
provision of this Agreement shall be construed so as to preclude such disclosure
of Confidential Information as may be inherent in or reasonably necessary for
marketing Products pursuant to this Agreement, or for securing from any
governmental agency any necessary approval or license relating to the subject or
performance of this Agreement.
6.3 Regulatory Requirements; Clinical Trials.
(a) Nissho will notify Delcath in a timely manner of all
applicable laws, rules and regulations affecting the importation, distribution,
sale and use of the Products in each
5
country in the Territory prior to ordering any Products intended for sale and
use in any such country.
(b) Protocols and Informed Consents used in clinical and
preclinical trials in each country in the Territory will be subject to the prior
approval of Nissho, Delcath and the MOH or other appropriate regulatory body in
the country in question. Delcath will be responsible for filing amendments to
its Investigatory Device Exemption to reflect the trials contemplated and
conducted.
(c) Nissho shall send to Delcath copies, in the original
language in which they were generated, of all reports and data from clinical
trials, and all correspondence with the regulatory authorities in all countries
in the Territory, including applications for regulatory approval, as soon as
reasonably practicable after such materials are available to Nissho. Upon the
request of Delcath, Nissho will provide Delcath with reasonable assistance in
translation of such materials into English, provided that Nissho shall be
indemnified for any costs incurred in connection with such assistance.
6.4 Non-Competition. Nissho agrees that from the date hereof until the date
falling two (2) years after the date of termination of this Agreement and the
exclusive distributorship created hereby except for the termination by Nissho
under Article 5.2(a), it shall not, directly or indirectly, anywhere in the
Territory, (i) engage in the business of manufacturing, distributing or selling
devices or systems which isolate specific organs or body regions for the
targeted delivery of anti-cancer compounds accompanied by the extra-corporeal
treatment of blood (the "Business") or assist, advise, represent or consult for
any other person or entity in connection with such person or entity engaging in
the Business, (ii) induce, or attempt to induce, any employee of Delcath to
leave such employ, or to accept any other position or employment or assist any
other person or entity in hiring such employee, (iii) solicit, or attempt to
solicit, any persons or entities who or which are customers of Delcath (as of
the date of termination of this Agreement or at any time prior thereto) in
connection with the engagement, by any person or entity, in the Business; or
(iv) otherwise disrupt or interfere with, or attempt to disrupt or interfere
with, Delcath's relations with any actual or potential customer or supplier or
any other material relationship of Delcath. For purposes of this Section 6.4,
the term "indirectly" shall include, without limitation, a reference to any
business or entity in which Nissho participates in the management, operation,
control or supervision or in which Nissho has any direct or indirect ownership
or financial interest, other than the direct or indirect beneficial ownership by
Nissho of less than four percent (4%) of the voting capital stock of a publicly
held corporation. The provisions of this Section 6.4 shall not apply in the
event this Agreement is rightfully terminated by Nissho under Section 5.2(a)(i)
hereof on account of Delcath's uncured breach of this Agreement.
6.5 Minimum Annual Purchase Quantities. Within twelve (12) months of the
date of regulatory approval of each Product for sale in each country in the
Territory, the parties shall agree upon a minimum quantity of that Product to be
purchased during the first full calendar year following such approval date. On
or before July 1 of each subsequent year, the parties shall agree upon a minimum
quantity of such Product to be purchased during the following calendar year for
resale and use in each such country. The minimum annual purchase quantity in
6
effect for a product for resale and use in a country in the Territory is herein
referred to as "Minimum Annual Purchase Quantity." Minimum Annual Purchase
Quantities shall be based on factors including the incidence of disease, cost of
the Delcath procedure, reimbursement amount and sales levels in other countries.
In the event that the parties are unable to agree on any Minimum Annual Purchase
Quantity either party may commence an arbitration proceeding as set forth in
Section 9.4 hereof.
6.6 Manufacturing License. Within twelve (12) months of the commencement of
sales anywhere in the Territory, Nissho and Delcath will commence discussions
concerning the possibility of Nissho becoming a manufacturer of any or all of
the components of the Products.
6.7 Facility Inspection. Nissho may from time to time designate a
representative who will visit Delcath's facilities to verify that quality
control procedures are consistent with requirements in the Territory. Such
visits will be preceded by reasonable notice, and will occur no more frequently
than once every two years.
VII. REPRESENTATIONS AND WARRANTIES
7.1 Manufacturing Standards. Delcath will manufacture Products in
accordance with (1) the Product Specifications; (2) Good Manufacturing Practices
("GMP") as required by the United States Food, Drug and Cosmetic Act; and (3)
pertinent rules and regulations of the United States Food and Drag
Administration (FDA). Delcath warrants that it will use reasonable care in the
manufacture of its Products and they will be free from defects in material and
workmanship under normal use and service.
7.2 Disclaimer of Warranties. NISSHO ACKNOWLEDGES AND AGREES THAT THE
EXPRESS WARRANTIES SET FORTH IN SECTION 7.1 HEREOF CONSTITUTE THE ENTIRE
WARRANTIES OF DELCATH WITH RESPECT TO THE PRODUCTS AND ARE IN LIEU OF ANY AND
ALL OTHER WARRANTIES, EXPRESSED OR IMPLIED, INCLUDING, WITHOUT LIMITATION, THE
IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.
7.3 Liability of Delcath. Notwithstanding any other term or condition of
this Agreement, Delcath shall have no liability to Nissho or to any third party
with respect to any claims arising out of or relating to the Products or their
use unless such claim stems from a claim under Section 7.1 or a latent or design
defect in the Products which was not the result of a design or process requested
by Nissho. In no event shall Delcath have any liability to Nissho or third
parties with respect to any Products which have been subjected to abuse, misuse,
improper use, negligence, accident, modification, alteration, tampering, failure
of the end-user to follow normal operating and maintenance procedures, attempted
repair by non-qualified personnel, operation outside of the normal environmental
and other specifications, or if the original identification (serial number,
trademark) markings have been defaced, altered or removed.
7.4 Limitation on Liability. Notwithstanding any other term or condition of
this Agreement, the total liability of Delcath, if any, and Nissho's sole and
exclusive remedy for damages for any claim of any kind whatsoever with respect
to any of Nissho's orders for the Products or with respect to any of the
7
Products covered thereby, regardless of the legal theory or the delivery or
non-delivery of the Products, shall not be greater than the actual purchase
price of the Products with respect to which such claim is made. UNDER NO
CIRCUMSTANCES SHALL DELCATH BE LIABLE TO NISSHO FOR ANY SPECIAL, INDIRECT,
INCIDENTAL OR CONSEQUENTIAL DAMAGES OF ANY KIND OR NATURE WHATSOEVER, INCLUDING,
BUT NOT LIMITED TO, REIMBURSEMENT FOR OR DAMAGES ON ACCOUNT OF (a) LOSS OF
PRESENT OR PROSPECTIVE PROFITS, EXPENDITURES, INVESTMENTS OR COMMITMENTS,
WHETHER MADE IN THE ESTABLISHMENT, DEVELOPMENT OR MAINTENANCE OF BUSINESS
REPUTATION OR GOODWILL, (b) LOSS OF DATA, (c) COST OF SUBSTITUTE PRODUCTS, (d)
COST OF CAPITAL, AND (e) CLAIMS OF ANY THIRD PARTY, REGARDLESS OF WHETHER OR NOT
DELCATH HAS BEEN APPRISED OF THE POSSIBILITY THEREOF. Delcath shall, however,
make available to Nissho any data from clinical trials, post-market
surveillance, manufacturing and quality assurance which can facilitate Nissho's
defense against claims made by a third party.
7.5 Performance. Delcath warrants that Products delivered to Nissho will,
when used in compliance with approved labeling, perform in accordance with data
in Delcath's PMA. Nissho will return to Delcath, at Nissho's expense, any
components deemed deficient from a performance standpoint, Delcath will promptly
attempt to reproduce the claimed nonperformance, upon verification of which it
will replace the deficient components at no cost to Nissho, and will credit
Nissho for freight charges incurred in making the return. If Delcath is unable
to reproduce the claimed nonperformance, no such replacement or credit will be
made.
VIII. OPTION FOR NEW PRODUCTS
8.1 First Right and Option. During the term of this Agreement, Delcath
grants Nissho the first right and option to obtain exclusive rights to market,
distribute and sell in the Territory, on the terms and conditions of this
Agreement or on other terms and conditions mutually acceptable to the parties,
any new devices or systems which isolate specific organs or body regions for the
targeted delivery of anti-cancer compounds accompanied by the extra-corporeal
treatment of blood.
8.2 Cooperation. If Nissho advises Delcath that it is interested in adding
a new product to this Agreement, Delcath and Nissho shall cooperate in all
reasonable ways required to give Nissho an opportunity to test market the demand
for such new product and in establishing the price and product specifications
therefor.
IX. MISCELLANEOUS
9.1 Notices. All notices, consents or other communications required or
permitted to be given pursuant to this Agreement shall be in writing and shall
be sent by facsimile. Any notices, consents or other communications given in
connection with the modification, extension or termination of this Agreement,
shall in addition be sent (a) by hand delivery, (b) by express mail for
overnight delivery (return receipt requested), (c) by certified or registered
mail (Return receipt requested), or (d) by recognized overnight courier service,
as follows:
8
If to Delcath: Delcath Systems, Inc.
0000 Xxxxxx Xxxxxx, 0xx Xxxxx
Xxxxxxxx, Xxxxxxxxxxx 00000
Attn: Mr. X.X. Xxxx
Fax: 00-000-000-0000
If to Nissho: Nissho Corporation
0-0-0 Xxxxx-Xxxxx
Xxxx-xx, Xxxxx 000, Xxxxx
Attn: Mr. Hiroshi Nikko
Fax: 00-0-000-0000
Such notice, consent or other communication shall be deemed given upon delivery
to the intended recipient.
9.2 Modification of Agreement. This Agreement may not be modified except by
an instrument or instruments in writing signed by an authorized representative
of the party against whom enforcement of such modification is sought. Either
party may, by an instrument in writing, waive compliance by the other party with
any term or provision of this Agreement. The waiver by either party hereto of a
breach of any term or provision of this Agreement shall not be construed as a
waiver of any subsequent breach.
9.3 Assignment. Neither party shall assign this Agreement or any part
thereof without the prior written consent of the other party; provided, however,
either party, without such consent, may assign or sell the same in connection
with the transfer or sale of substantially its entire business to which this
Agreement pertains or in the event of its merger or consolidation with another
company. Any permitted assignee shall assume all obligations of its assignor
under this Agreement. No assignment shall relieve any party of responsibility
for the performance of any accrued obligation which such party then has
hereunder.
9.4 Arbitration. Any controversy or claim arising out of or relating to
this Agreement, including any question regarding its existence, validity or
termination shall be settled by arbitration in accordance with the Commercial
Arbitration Rules of the American Arbitration Association, and judgment upon the
award rendered by the arbitrators may be entered into any court having
jurisdiction thereof. The place of arbitration shall be Honolulu, Hawaii, and
the language of arbitration shall be English. The panel shall consist of three
arbitrators, two of whom shall be nominated by the respective parties.
9.5 Force Majeure. Any delay in the performance of any of the duties or
obligations of either party hereto shall not be considered a breach of this
Agreement and the time required for performance shall be extended for a period
equal to the period of such delay; provided that such delay has been caused by
or is the result of any acts of God, acts of the public enemy, insurrections,
riots, embargoes, labor disputes, including strikes, lockouts, job actions, or
boycotts, fires, explosions, floods, shortages of material or energy or other
unforeseeable causes beyond the control and without the fault or negligence of
the party so affected. The party so affected shall give prompt notice to the
9
other party of such cause, and shall take whatever reasonable steps are
necessary to relive the effect of such cause as rapidly as possible.
9.6 Regulatory Compliance. Each party shall use its best reasonable efforts
to obtain all regulatory approvals necessary for its performance hereunder, but
shall sustain no liability to the other party for its failure to perform if such
performance would be in violation of any law, rule or regulation applicable to
such party.
9.7 Entire Agreement. This Agreement constitutes the entire agreement and
understanding between the parties and supersedes any and all prior agreements
and understandings, whether written or oral.
9.8 Relationship of Parties. Neither Delcath on the one hand nor Nissho
on the other, nor any of their respective agents, employees, officers,
directors, independent contractors or representatives shall (a) be considered as
an agent, partner, joint venturer, employee, or representative of the other
party for any purpose whatsoever, (b) have any authority to make any agreement
or commitment for, or to incur any liability or obligation in the other party's
name or for or on its behalf, and (c) represent to outside parties that they or
any of them has any right to bind the other party to this Agreement.
9.9 Governing Law. The validity and interpretation of this Agreement shall
be governed by and construed in accordance with the laws of the State of
Connecticut, without regard to principles of conflict of laws.
9.10 Headings. The headings contained in this Agreement are for convenience
and reference purposes only and shall not affect the meaning or interpretation
of this Agreement.
9.11 Counterparts. This Agreement may be executed in any number of
counterparts, any one of which (or any set of which) when signed by all parties
shall constitute an original agreement.
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
executed by their duly authorized officers the day and year first above written.
DELCATH SYSTEMS, INC. NISSHO CORPORATION
By: /s/ X.X. Xxxx By: /s/ Xxxxxx Xxxx
-------------------------------- ------------------------------------
Name: X.X. Xxxx Name: Xxxxxx Xxxx
Title: Chief Executive Officer Title: President
10
SCHEDULES
---------
A. Patents
B. Products and Product Specifications
C. Order and Forecast Procedure
D. Prices
11
SCHEDULE A
----------
PATENTS
-------
The Corporation has four issued patents assigned to it: two United States, one
Canadian, and one European:
1) U.S. Patent #5,069,662, dated December 3, 1991. Inventor: Xxxxxxx X.
Xxxxxx
2) U.S. Patent # 5,411,479 dated May 2, 1995. Inventor: Xxxxxxx X. Xxxxxx
3) Canadian Patent # 1,333,872 dated January 10, 1995. Inventor: Xxxxxxx
X. Xxxxxx
4) European Patent # 0 364 799 - granted May 3, 1995 and applying for
registration in EC Countries. Inventor: Xxxxxxx X. Xxxxxx
The Corporation has three patent applications assigned to it:
1) Japanese Patent Application. Inventor: Xxxxxxx X. Xxxxxx
2) U.S. Patent Application # 706,186
3) U.S. Patent Application # 708,046
12
SCHEDULE B
----------
PRODUCTS AND PRODUCT SPECIFICATIONS
-----------------------------------
A. Products
1. The Delcath System Kit - Liver (Includes double balloon
catheter, introducer set, filters, pump head, flow probe,
hepatic infusion catheter, return sheath and extracorporeal
circuit)
2. The Delcath System Kit - Lower Extremities (Same components
as Liver Kit are anticipated.)
B. Product Specifications
Except as otherwise agreed by the parties, the Product Specifications
shall be identical to those utilized in Delcath's Pre-Marketing
Approval ("PMA") application and shall be made available to Nissho
within sixty (60) days after the execution and delivery of this
Agreement.
Delcath shall provide Nissho with six (6) months' advance notice of any
changes to its Product Specifications. Nissho will promptly inform
Delcath of any aspects of Delcath's Product Specifications which may
hinder the regulatory approval process in any country in the Territory,
and will work with Delcath to resolve such aspects to their mutual
satisfaction.
13
SCHEDULE C
----------
ORDER AND FORECAST PROCEDURE
----------------------------
Nissho shall place an Initial Order for each Product within ninety (90)
days of the regulatory approval of, and in countries where applicable,
establishment of a reimbursement price for, said Product anywhere in the
Territory. Subsequent orders for that Product shall be placed no less frequently
than quarterly and no more frequently than monthly.
On the first business day of each January, April, July and October, and
at other times when changing conditions lead to substantial shifts in
expectations, Nissho shall provide Delcath with its best estimate of anticipated
orders, by product by country by month, for the subsequent twelve (12) months.
These estimates will be used to facilitate the production and distribution
processes, and shall have no bearing on the minimum annual purchase quantities
referred to in Section 6.5
14
SCHEDULE D
----------
PRICES
------
The prices of Products shall be in United States Dollars as mutually
agreed by the parties.
Delcath shall issue a Price List on the first day of each September.
All prices shall go into effect on the first day of the following January, and
shall remain in effect for one (1) year.
15
